Abstract
ABSTRACT Optimal systemic therapy still is the most important modality in metastatic breast cancer. However, improved imaging and diagnostic tools combined with biological targeted systemic therapies and possibilities to 3D conformal and stereotactic radiotherapy make new possibilities in multidisciplinary approaches of metastatic/oligometastic breast cancer. The presentation will review data (as well as paucity of data) regarding effects of extensive locoregional radiotherapy in metastatic breast cancer, concurrent radiochemo approaches in advanced breast cancer and data on combination of radiotherapy and systemic therapy in the treatment of metastatic disease in different sites. The selection bias of the published retrospective series will be addressed as well as what we may learn in the future from analyzing treatments and patient related factors in long-term survivors among patients with metastatic breast cancer. Disclosure: The author has declared no conflicts of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
